公开(公告)号：US20180237762A1

公开(公告)日：2018-08-23

申请号：US15866203

申请日：2018-01-09

Applicant: Bioverativ Therapeutics Inc.

Inventor： Daniel S. Rivera ,  Robert T. Peters ,  Alan J. Bitonti

IPC: C12N9/64 ,  C07K16/18 ,  A61K38/48 ,  A61K45/06 ,  A61K38/36 ,  C07K14/745 ,  A61K47/68 ,  A61K39/00

Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.

公开(公告)号：US20170266309A1

公开(公告)日：2017-09-21

申请号：US15465319

申请日：2017-03-21

Applicant: Bioverativ Therapeutics Inc.

Inventor： Robert T. PETERS ,  Adam R. Mezo ,  Daniel S. Rivera ,  Alan J. Bitonti ,  Susan C. Low

IPC: C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K16/00 ,  C12N9/64 ,  C12N9/96

Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.